Gaudium IVF and Women Health Limited, India's first publicly listed IVF chain, has inaugurated a new fertility centre in South Extension, New Delhi, marking the first milestone in its planned 19-centre expansion announced during its initial public offering (IPO).

The new facility strengthens the company's strategy of expanding access to technology-enabled fertility care through a standardized clinical and laboratory model focused on consistent patient outcomes.

The South Delhi centre offers comprehensive fertility services under one roof, combining fertility specialists, reproductive medicine expertise and Gaudium IVF's standardized clinical protocols. 

Central to the facility is the Gaudium Signature Lab, the company's proprietary laboratory framework that integrates advanced embryology, artificial intelligence and internationally benchmarked quality standards to support embryo development.

Gaudium IVF said the Signature Lab model will be replicated across all upcoming centres to ensure uniform standards of precision, safety and clinical excellence across its expanding network.

The centre is equipped with the company's AI-powered embryology ecosystem, including SiD (Sperm Identification Device) for advanced sperm assessment and ERICA (Embryo Ranking Intelligent Classification Assistant) for embryo evaluation. According to the company, these technologies complement embryologists' expertise by providing data-driven insights that improve precision and consistency during the IVF process.

Dr. Manika Khanna, Chairperson and Managing Director, Gaudium IVF, said, "The launch of our South Extension centre reflects our commitment to making world-class fertility care more accessible without compromising on the standards that have guided us for the past 17 years. As we expand our network, our focus remains on building centres that combine scientific excellence, AI-powered innovation and globally benchmarked laboratory standards with a patient-first approach."